Drug Trial Radar · NCT04408963
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Mar 22, 2022
Primary completion
Nov 28, 2022
Study completion Nov 28, 2022
Sponsor
- Sponsor type
- NIH
- First posted
- Jun 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs. Researchers want to test an antibody, CAP256V2LS. Objective: To test CAP256V2LS to see if it is safe and how the body responds to it. Eligibility: Healthy people, ages 18-60 Design: Participants were screened with a medical history, physical exam, and blood tests. Some females had a pregnancy test. Participants were assigned to one of two groups. Based on their group, they got 1 dose of CAP256V2LS in 1 of 2 ways: * Some participants got CAP256V2LS as an infusion. A thin tube was placed in an arm vein and CAP256V2LS was given into the vein using a pump. * Some participants got CAP256V2LS injected under the skin. A small needle was used to inject CAP256V2LS into the fatty tissue of the belly, arm, or thigh. They got 1 to 4 injections. On the day they got CAP256V2LS, participants gave blood samples at different time points. Participants were asked to check their temperature every day for 7 days after receiving CAP256V2LS. They used a tool to measure any redness, swelling, or bruising they may have at the site where they received the study drug. Participants had visits at least 2-3 times during the first week after they got CAP256V2LS. Then they had about 9 more visits over the next 6 months. Visits included blood tests.
Conditions
- HIV
Interventions
VRC-HIVMAB0102-00-ABBiological
The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CAP256V2LS Product AdministrationTime frame: 7 days after CAP256V2LS product administration, at approximately Week 1
- Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of CAP256V2LS Product AdministrationTime frame: 7 days after CAP256V2LS product administration, at approximately Week 1
- Number of Participants With One or More Unsolicited Non-Serious Adverse Events (AEs) Following CAP256V2LS Product AdministrationTime frame: Day 0 through 4 weeks after CAP256V2LS Product Administration
- Number of Participants With Serious Adverse Events (SAEs) Following CAP256V2LS Product AdministrationTime frame: Day 0 after CAP256V2LS product administration through the study participation, up to Week 24
- Number of Participants With New Chronic Medical Conditions Following CAP256V2LS Product AdministrationTime frame: Day 0 after CAP256V2LS product administration through the study participation, up to Week 24
- Number of Participants With Abnormal Laboratory Measures of Safety Following CAP256V2LS Product AdministrationTime frame: Day 0 through 4 weeks after CAP256V2LS Product Administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.